Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has long been familiar with the potential of psychedelics. A recent article, which contains excerpts from a New York Times writeup entitled “The Psychedelic Revolution Is Coming,” documents the increased urgency to develop new therapeutics. “This urgency aligns with Silo Pharma’s mission of identifying assets to license while funding transformative research for the well-being of patients and the health care industry. Silo Pharma focuses specifically on patients suffering from largely underserved indications like post-traumatic stress disorder (‘PTSD’), fibromyalgia, Alzheimer’s, Parkinson’s, and other rare neurological disorders,” the article reads. “The company has filed four U.S. provisional patent applications and a pipeline including a research collaboration with Columbia University and UCSF; an investigator-led sponsored study with Maastricht University; an option agreement with the University of Maryland, Baltimore for patented homing peptides targeting rheumatoid arthritis; licensing for a patented novel peptide-guided drug-delivery approach for the treatment of multiple sclerosis; and upfront funding for a licensing deal for its psilocybin cancer therapeutic applications.”

To view the full article, visit https://ibn.fm/kdF1E

About Silo Pharma Inc.

Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s, Parkinson’s and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which the company believes will be transformative to the well-being of patients and the health care industry. For more information about the company, visit www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.